A Comparative Review of Autologous Conditioned Serum and Autologous Protein Solution for Treatment of Osteoarthritis in Horses.
Authors: Camargo Garbin Livia, Morris Michael J
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Osteoarthritis in horses involves complex inflammatory cascades centred on interleukin-1 beta (IL-1β), which drives cartilage degradation and joint dysfunction. Two blood-derived autologous therapies—autologous conditioned serum (ACS) and autologous protein solution (APS)—have emerged as potential disease-modifying treatments, both functioning by enriching interleukin-1 receptor antagonist (IL-1Ra) and other bioactive factors that compete with IL-1β signalling without triggering the same inflammatory cascade. This narrative review synthesised evidence from in vitro and in vivo studies to directly compare ACS and APS products, their mechanisms, composition variability, and clinical efficacy in equine OA management. Whilst both therapies demonstrate anti-inflammatory potential and clinicians report promising outcomes, critical gaps remain: product composition varies significantly between commercial kits and production methods, the synergistic effects of multiple cytokines and growth factors within each preparation remain incompletely characterised, and clinical response variability across individual horses lacks adequate prognostic markers. Understanding these distinctions between ACS and APS—alongside their respective concentrations of bioactive compounds and optimal application protocols—is essential for evidence-based decision-making, particularly given the considerable cost and need for informed client counselling regarding realistic treatment expectations and the current limitations of our understanding of joint-level responses to these interventions.
Read the full abstract on PubMed
Practical Takeaways
- •ACS and APS are cytokine-modulating therapies targeting IL-1β in joint disease; both show promise but differ in production methods and may have variable clinical results depending on patient factors
- •These are blood-derived products with anti-inflammatory properties that may slow OA progression, but clinicians should understand that clinical outcomes vary and further research is needed to predict individual response
- •When considering ACS or APS for joint disease, recognize that both work through similar mechanisms (IL-1Ra elevation) but clients and clinicians should understand the practical differences between the two approaches before choosing treatment
Key Findings
- •IL-1β blockade through IL-1Ra represents a promising approach for modulating osteoarthritis progression in horses
- •Both ACS and APS are blood-derived products that achieve high concentrations of IL-1Ra and other anti-inflammatory cytokines and growth factors
- •In vitro and in vivo studies demonstrate potential anti-inflammatory effects of ACS and APS, though clinical outcomes vary
- •Product composition and component interactions in joint inflammation require further research for optimal therapeutic application